GeneOne Life Science Responds to Inquiry on Subsidiary VGXI Texas Factory Ownership Transfer - Transaction Is Effectively a Secured Loan with Limited Shareholder Value Impact
The contract between GeneOne Life Science's subsidiary VGXI and C2R Secured Funding LLC involves a transfer of Texas factory ownership in form but is substantively a mortgage loan.
Total loan amount is USD 14.3 million consisting of a credit loan of USD 13.3 million and a real estate mortgage of USD 1.0 million, corrected from an earlier erroneous figure of USD 1 billion.
Due to retained repurchase rights and control over the asset, the factory remains on the books as a tangible asset, confirming the transaction is not a true sale.
The loan repayment deadline is September 1, 2026, and further disclosure will be made at that time.
This transaction involves no new share issuance or capital structure change, thus no dilution of existing shareholder value.
[AI Summary]GeneOne Life Science's funding is defensive debt refinancing without equity dilution. The counterparty is a private investment fund with limited transparency. Monitoring is required at maturity in September 2026.
KOSPI Filing Information
[Correction of Description] Reply to Inquiry Disclosure Request (Rumor or News Report) (Denial)